Table 2.
Summaries of the high risk predictors by whether a composite event occurred, excluding chronic DVTs
| No composite event (N = 589) |
Composite event (N = 74) |
||||
|---|---|---|---|---|---|
| Factor | N | Statistics | N | Statistics | p-value |
| HIV (0/1) | 587 | 5 (0.85) | 74 | 0 (0.00) | 0.99d |
| Adenovirus (0/1) | 100 | 3 (3.0) | 16 | 0 (0.00) | 0.99d |
| Parvovirus (0/1) | 22 | 7 (31.8) | 3 | 1 (33.3) | 0.99d |
| RSV (0/1) | 130 | 7 (5.4) | 18 | 0 (0.00) | 0.60d |
| EBV (0/1) | 101 | 69 (68.3) | 15 | 7 (46.7) | 0.10c |
| Previous COVID | 589 | 75 (12.7) | 74 | 10 (13.5) | 0.85c |
| Omeprazole (0/1) | 589 | 113 (19.2) | 74 | 16 (21.6) | 0.62c |
| Cimetidine (0/1) | 589 | 0 (0.00) | 74 | 0 (0.00) | |
| Ranitidine (0/1) | 589 | 4 (0.68) | 74 | 0 (0.00) | 0.99d |
| Rifampin (0/1) | 589 | 3 (0.51) | 74 | 0 (0.00) | 0.99d |
| Quinidine (0/1) | 589 | 0 (0.00) | 74 | 0 (0.00) | |
| Carbamazepine (0/1) | 589 | 1 (0.17) | 74 | 0 (0.00) | 0.99d |
| Pantoprazole (0/1) | 589 | 228 (38.7) | 74 | 27 (36.5) | 0.71c |
| Bactrim (0//1) | 589 | 69 (11.7) | 74 | 8 (10.8) | 0.82c |
| Aspirin (0/1) | 589 | 257 (43.6) | 74 | 30 (40.5) | 0.61c |
| Clopidogrel (0/1) | 589 | 35 (5.9) | 74 | 8 (10.8) | 0.13d |
| Ticagrelor (0/1) | 589 | 4 (0.68) | 74 | 1 (1.4) | 0.45d |
| Prednisone (0/1) | 589 | 107 (18.2) | 74 | 13 (17.6) | 0.90c |
| Hydrochlorothiazide (0/1) | 589 | 72 (12.2) | 74 | 7 (9.5) | 0.49c |
| Vancomycin (0/1) | 589 | 83 (14.1) | 74 | 12 (16.2) | 0.62c |
| Spironolactone (0/1) | 589 | 53 (9.0) | 74 | 3 (4.1) | 0.15c |
| Chemo (0/1) | 589 | 282 (47.9) | 74 | 39 (52.7) | 0.43c |
Statistics presented as N (column %)
p-values: c = Pearson’s chi-square test, d = Fisher’s Exact test